ACM
RCUS icon

Anfield Capital Management’s Arcus Biosciences RCUS Stock Holding History

Anfield Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-8,041
Closed -$109K – 599
2025
Q3 		$109K Hold
8,041
– – 0.03% 120
2025
Q2 		$65.5K Hold
8,041
– – 0.02% 145
2025
Q1 		$63.1K Hold
8,041
– – 0.02% 129
2024
Q4 		$120K Hold
8,041
– – 0.04% 86
2024
Q3 		$123K Hold
8,041
– – 0.05% 87
2024
Q2 		$122K Hold
8,041
– – 0.06% 73
2024
Q1 		$152K Buy
+8,041
New +$139K 0.07% 72
2023
Q1 		– Sell
-531
Closed -$11K – 87
2022
Q4 		$11K Sell
531
-7,510
-93% -$207K 0.01% 85
2022
Q3 		$210K Hold
8,041
– – 0.1% 71
2022
Q2 		$204K Hold
8,041
– – 0.09% 73
2022
Q1 		$254K Hold
8,041
– – 0.09% 74
2021
Q4 		$325K Hold
8,041
– – 0.11% 65
2021
Q3 		$275K Hold
8,041
– – 0.09% 76
2021
Q2 		$221K Hold
8,041
– – 0.08% 66
2021
Q1 		$226K Hold
8,041
– – 0.09% 80
2020
Q4 		$209K Buy
+8,041
New +$195K 0.09% 82
2020
Q1 		– Sell
-8,041
Closed -$76K – 312
2019
Q4 		$76K Buy
+8,041
New +$67.6K 0.03% 190

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Anfield Capital Management's RCUS Position: Q4 2025 in Review

Anfield Capital Management sold out of Arcus Biosciences (RCUS) in Q4 2025, closing a stake of 8,041 shares — an estimated $109K sold.

Anfield Capital Management first reported a position in RCUS in Q4 2019 and held it in 17 quarters. The position peaked at $325K in Q4 2021. 209 funds tracked by Wall St. Rank hold RCUS as of Q4 2025.

  • Anfield Capital Management reported no remaining Arcus Biosciences position as of Q4 2025 after selling out during the quarter.
  • Anfield Capital Management sold 8,041 Arcus Biosciences shares in Q4 2025, an estimated $109K.
  • Anfield Capital Management first reported a position in Arcus Biosciences in Q4 2019 and held it in 17 quarters.
  • Anfield Capital Management's Arcus Biosciences position peaked at $325K in Q4 2021.
  • 209 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2025.

Based on Anfield Capital Management's 13F filing for Q4 2025, filed 3 Feb 2026.